Physician profile
Michael Moses
NPI 1750465324
$3,748.60
in general payments reported to CMS, 2019-2025
15 companies · $460 in 2025
The $460 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $180 · 2021: $61.92 · 2022: $846 · 2023: $836 · 2024: $787 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $850.69 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Durasorb Monofilament Mesh |
| Mentor Worldwide LLC | $568.75 | 2019-2024 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $320.63 | 2019-2022 | |
| Tela Bio, INC. | $288.57 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Abbvie INC. | $249.41 | 2023-2025 | |
| Merz North America, INC. | $240.68 | 2019-2023 | Xeomin |
| Allergan, INC. | $225.41 | 2019-2021 | |
| Davol INC. | $222.06 | 2022 | |
| Revance Therapeutics, INC. | $164.36 | 2024-2025 | Daxi |
| Baxter Healthcare | $160.83 | 2019-2023 | Artiss |
| Lumenis Be INC | $148.10 | 2022 | |
| Smith+Nephew, INC. | $124.31 | 2019 | |
| Acera Surgical, INC. | $90.35 | 2024 | Restrata Wound Matrix |
| Motiva USA, LLC | $66.92 | 2024-2025 | |
| Galderma Laboratories, L.P. | $27.53 | 2023-2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.